148 related articles for article (PubMed ID: 29334534)
21. Asparaginase
Gao C; Ma X; Zhang Z; Lu Q; Ashby CR; Wei L; Chen ZS
Drugs Today (Barc); 2022 Jun; 58(6):261-271. PubMed ID: 35670704
[TBL] [Abstract][Full Text] [Related]
22. Symptomatic hyperammonemia secondary to recombinant Erwinia asparaginase.
Martin CE; Kohorst MA; Ferdjallah A; Kalmes JL; Johnson HM; Galardy PJ; Khan SP; Kuhn AK
Pediatr Blood Cancer; 2023 May; 70(5):e30208. PubMed ID: 36633209
[No Abstract] [Full Text] [Related]
23. Rapid large-scale preparation of recombinant Erwinia chrysanthemi L-asparaginase.
Goward CR; Stevens GB; Tattersall R; Atkinson T
Bioseparation; 1992; 2(6):335-41. PubMed ID: 1368993
[TBL] [Abstract][Full Text] [Related]
24. Anti-Erwinia asparaginase antibodies during treatment of childhood acute lymphoblastic leukemia and their relationship to outcome: a case-control study.
Klug Albertsen B; Schmiegelow K; Schrøder H; Carlsen NT; Rosthøj S; Avramis VI; Jakobsen P
Cancer Chemother Pharmacol; 2002 Aug; 50(2):117-20. PubMed ID: 12172975
[TBL] [Abstract][Full Text] [Related]
25. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
Kwok CS; Kham SK; Ariffin H; Lin HP; Quah TC; Yeoh AE
Pediatr Blood Cancer; 2006 Sep; 47(3):299-304. PubMed ID: 16302217
[TBL] [Abstract][Full Text] [Related]
26. Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report.
Ko RH; Jones TL; Radvinsky D; Robison N; Gaynon PS; Panosyan EH; Avramis IA; Avramis VI; Rubin J; Ettinger LJ; Seibel NL; Dhall G
Cancer; 2015 Dec; 121(23):4205-11. PubMed ID: 26308766
[TBL] [Abstract][Full Text] [Related]
27. Beta-aspartylpeptides as substrates of L-asparaginases from Escherichia coli and Erwinia chrysanthemi.
Kelo E; Noronkoski T; Stoineva IB; Petkov DD; Mononen I
FEBS Lett; 2002 Sep; 528(1-3):130-2. PubMed ID: 12297292
[TBL] [Abstract][Full Text] [Related]
28. Optimizing asparaginase therapy for acute lymphoblastic leukemia.
Rizzari C; Conter V; Starý J; Colombini A; Moericke A; Schrappe M
Curr Opin Oncol; 2013 Mar; 25 Suppl 1():S1-9. PubMed ID: 23380829
[TBL] [Abstract][Full Text] [Related]
29. Multiple Asparaginase Infusions Cause Increasingly Severe Acute Hyperammonemia.
Buddington RK; Buddington KK; Howard SC
Med Sci (Basel); 2022 Aug; 10(3):. PubMed ID: 35997335
[TBL] [Abstract][Full Text] [Related]
30. High incidence of symptomatic hyperammonemia in children with acute lymphoblastic leukemia receiving pegylated asparaginase.
Heitink-Pollé KM; Prinsen BH; de Koning TJ; van Hasselt PM; Bierings MB
JIMD Rep; 2013; 7():103-8. PubMed ID: 23430503
[TBL] [Abstract][Full Text] [Related]
31. Erwinia asparaginase in pediatric acute lymphoblastic leukemia.
Salzer W; Seibel N; Smith M
Expert Opin Biol Ther; 2012 Oct; 12(10):1407-14. PubMed ID: 22946493
[TBL] [Abstract][Full Text] [Related]
32. Atomic resolution structure of Erwinia chrysanthemi L-asparaginase.
Lubkowski J; Dauter M; Aghaiypour K; Wlodawer A; Dauter Z
Acta Crystallogr D Biol Crystallogr; 2003 Jan; 59(Pt 1):84-92. PubMed ID: 12499544
[TBL] [Abstract][Full Text] [Related]
33. [Molecular basis of hyperammonemia secondary to asparaginase: from therapeutic efficacity to toxicity].
Gallin M; Damaj L; Gandemer V; Bendavid C; Moreau C
Ann Biol Clin (Paris); 2023 Oct; 81(4):365-377. PubMed ID: 37864442
[TBL] [Abstract][Full Text] [Related]
34. Structural Insight into Substrate Selectivity of Erwinia chrysanthemi L-asparaginase.
Nguyen HA; Su Y; Lavie A
Biochemistry; 2016 Mar; 55(8):1246-53. PubMed ID: 26855287
[TBL] [Abstract][Full Text] [Related]
35. L-Asparaginase from Erwinia Chrysanthemi 3937: cloning, expression and characterization.
Kotzia GA; Labrou NE
J Biotechnol; 2007 Jan; 127(4):657-69. PubMed ID: 16984804
[TBL] [Abstract][Full Text] [Related]
36. Validation of a 30-year-old process for the manufacture of L-asparaginase from Erwinia chrysanthemi.
Gervais D; Allison N; Jennings A; Jones S; Marks T
Bioprocess Biosyst Eng; 2013 Apr; 36(4):453-60. PubMed ID: 22907565
[TBL] [Abstract][Full Text] [Related]
37. [Acute pancreatitis in children with acute lymphoblastic leukemia treated with L-asparaginase].
Wlazłowski M; Celińska W; Maciejka-Kapuścińska L; Płoszyńska A; Idczak E
Pol Tyg Lek; 1994 Mar 21-28; 49(12-13):296-7. PubMed ID: 7808958
[TBL] [Abstract][Full Text] [Related]
38. Negligible hemostatic toxicity of intermediate-dose Erwinase in adult patients with acute lymphoblastic leukemia: preliminary data.
Nocentini F; Gugliotta L; Catani L; Vianelli N; Baravelli S; Martelli V; Tura S
Haematologica; 1994; 79(6):546-9. PubMed ID: 7896215
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future.
Avramis VI; Panosyan EH
Clin Pharmacokinet; 2005; 44(4):367-93. PubMed ID: 15828851
[TBL] [Abstract][Full Text] [Related]
40. Effects of Erwinia-asparaginase on the coagulation system.
Carlsson H; Stockelberg D; Tengborn L; Braide I; Carneskog J; Kutti J
Eur J Haematol; 1995 Nov; 55(5):289-93. PubMed ID: 7493674
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
